Paroxysmal Nocturnal Hemoglobinuria Clinical Trial
Official title:
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
This phase II trial tests whether treosulfan, fludarabine, and rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant (conditioning regimen) to cause fewer complications for patients with bone marrow failure diseases. Chemotherapy drugs, such as treosulfan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fludarabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. rATG is used to decrease the body's immune response and may improve bone marrow function and increase blood cell counts. Adding treosulfan to a conditioning regimen with fludarabine and rATG may result in patients having less severe complications after a blood or bone marrow transplant.
| Status | Recruiting |
| Enrollment | 40 |
| Est. completion date | December 2026 |
| Est. primary completion date | December 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 49 Years |
| Eligibility | Inclusion Criteria: - Patient must be >= 1.0 year of age and less than 50.0 years of age at the time of enrollment (i.e. patient must have celebrated their 1st birthday when enrolled and must NOT have celebrated their 50th birthday when enrolled; 49.99 years) - Underlying BMFD treatable by allogenic HCT - Shwachman-Diamond syndrome - Criteria for Diagnosis: - A pathogenic mutation(s) for Shwachman-Diamond syndrome - For those patients tested but lacking a genetic mutation they must meet both *** criteria below: - Exocrine pancreatic dysfunction as defined by at least one of the following: - Pancreatic isoamylase below normal (age >= 3 years old), OR - Fecal elastase < 200, AND - Bone marrow failure as evidence by at least one of the following: - Intermittent or persistent neutropenia (absolute neutrophil count < 1,500/uL), OR - Hypo-productive anemia with a hemoglobin concentration below the age-related adjusted norms, OR - Unexplained macrocytosis, OR - Platelet count < 150,000/uL without alternative etiology, OR - Hypocellular bone marrow - Indications for HCT: - Severe neutropenia (absolute neutrophil count [ANC] < 500/uL), OR - Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR - Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 eligibility review committee (ERC). In addition, patients with severe or recurrent infections will be reviewed by the ERC if they do not meet the indications for transplant listed above - Diamond Blackfan Anemia - Criteria for Diagnosis: - A pathogenic mutation for Diamond Blackfan anemia - For those patients tested but lacking a genetic mutation the patient must meet the first *** criteria and at least one of the subsequent *** criteria listed below: - History of deficiency of erythroid precursors in an otherwise cellular bone marrow AND, - Reticulocytopenia, OR - Elevated adenosine deaminase activity, OR - Elevated hemoglobin F, OR - Macrocytosis, OR - Congenital anomalies - Indications for HCT: - Red blood cell (RBC) transfusion dependent anemia despite an adequate trial of steroids; OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC - Congenital Sideroblastic anemia - Criteria for Diagnosis: - A pathogenic mutation(s) for sideroblastic anemia - For those patients tested but lacking a genetic mutation: - Presence of ringed sideroblasts in the bone marrow excluding acquired causes of ringed sideroblasts such as lead poisoning & zinc toxicity - Indications for HCT: - Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC - GATA2 mutation with associated marrow failure - Criteria for Diagnosis: ** A pathogenic mutation(s) for GATA2 - Indications for HCT: - Severe neutropenia (ANC < 500/uL), OR - Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR - Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC. In addition, patients with severe or recurrent infections will be reviewed by the ERC if they do not meet indications for transplant listed above - SAMD9 or SAMD9L disorders - Criteria for Diagnosis: ** A pathogenic mutation(s) for SAMD9 or SAMD9L - Indications for HCT: - Severe neutropenia (ANC < 500/uL), OR - Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR - Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC - Congenital amegakaryocytic thrombocytopenia - Criteria for Diagnosis: - A pathogenic mutation(s) for congenital amegakaryocytic thrombocytopenia. - For those patients tested but lacking a genetic mutation the patient must meet criteria below: - Thrombocytopenia early in life, AND - History of bone marrow demonstrating megakaryocyte hypoplasia - Indications for HCT: - Severe thrombocytopenia (platelet count < 20,000/uL) or transfusion-dependent thrombocytopenia, OR - Neutropenia defined as an ANC < 500/uL, OR - Severe anemia (hemoglobin < 8 g/dL) or transfusion-dependent anemia, OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC - Paroxysmal nocturnal hemoglobinuria - Criteria for Diagnosis: - Paroxysmal nocturnal hemoglobinuria (PNH) clone size in granulocytes >= 10%, AND - Complement mediated intravascular hemolysis with an elevated LDH (above institutional upper limits of normal) - Indications for HCT: - PNH with thrombosis despite adequate medical management, OR - PNH with intravascular hemolysis requiring transfusion support despite adequate medical management, OR - Additional clinical or laboratory data may be considered for protocol eligibility following review by protocol 1904 ERC. In addition, patients with PNH and cytopenias may be considered for the protocol eligibility following review by protocol 1904 ERC - An undefined BMFD: a patient with a BMFD for whom a genetic mutation responsible for their bone marrow failure phenotype has not been identified (excluding PNH) will be eligible for this clinical trial following approval by Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1904 ERC * A BMFD with a known genetic mutation but not listed above will be eligible for this clinical trial following approval by BMT CTN 1904 ERC - Patient and/or legal guardian must sign informed consent prior to initiation of conditioning for BMT CTN 1904 - Note: The following patients MUST be reviewed by the BMT CTN 1904 ERC in order to determine if they are eligible for this trial: - All patients with Shwachman-Diamond syndrome, Diamond Blackfan anemia, congenital sideroblastic anemia, and congenital amegakaryocytic thrombocytopenia who have had genetic testing and a genetic mutation responsible for their disease was not identified - All patients with an undefined BMFD: a patient with a BMFD for whom a genetic mutation responsible for their bone marrow failure phenotype has not been identified, excluding PNH - All patients with a BMFD and a known genetic mutation that is not listed above - All patients with GATA2 mutation and associated marrow failure - All patients with SAMD9 or SAMD9L disorders - There may be circumstances where a treating physician will consider a transplant for a patient with a BMFD who does not meet all the criteria listed under "indications for HCT". In these situations, treating physicians may submit their patient to the BMT CTN 1904 ERC for review in order to determine if the patient is eligible for this clinical trial based on additional clinical or laboratory information - Many patients with BMFD can have bone marrow evaluations that raise concern for possible myelodysplastic syndrome (MDS) including but not limited to dysplastic bone marrow evaluations or cytogenetic abnormalities. However, in patients BMFD these findings are not necessarily diagnostic or consistent with MDS. Therefore, given the complexities of diagnosing MDS in patients with BMFD, all patients with bone marrow evaluations concerning for possible MDS should be submitted to the ERC for review to confirm or exclude MDS. This is particularly important as we do not want to exclude potentially eligible patients due to an incorrect diagnosis of MDS - HLA-MATCHED RELATED DONOR: HLA-matched sibling: Must be a minimum HLA-6/6 matched to the recipient at HLA-A, -B (serologic typing) and DRB1 (high-resolution typing) - HLA-MATCHED RELATED DONOR: HLA-matched related (phenotypic match): Fully matched for HLA-A, -B, -C, -DRB1, and DQB1 by high-resolution typing. - HLA-MATCHED RELATED DONOR: If a genetic mutation is known for the patient, the HLA-matched related donor [either HLA-matched sibling or HLA-matched related (phenotypic match)] must be screened for the same genetic mutation if clinically appropriate and should be confirmed to not have the same genetic disease (this does not include patients with PNH). Consult the protocol team with questions - HLA-MATCHED RELATED DONOR: If a patient has an undefined BMFD (a patient with a BMFD for whom a genetic mutation responsible for their bone marrow failure phenotype has not been identified), the HLA-matched related donor [either HLA-matched sibling or HLA-matched related (phenotypic match)] must have an evaluation as directed by the treating physician to confirm that the donor does not have the same underlying disease. This will include a complete blood count (CBC) with differential and potentially a bone marrow evaluation or other studies as directed by the treating physician - UNRELATED DONOR: Fully matched for HLA-A, -B, -C, -DRB1, and DQB1 by high-resolution typing OR - UNRELATED DONOR: Mismatched for a single HLA-class 1 allele (HLA-A, -B, or -C) by high-resolution typing; OR - UNRELATED DONOR: Mismatched for a single HLA DQB1 allele or antigen by high-resolution typing * Note: donor patient (DP) matching per institutional practice - DONOR SELECTION RECCOMENDATIONS: in the case where there are multiple donor options, donors should be selected based on the following priority numbered below: - Unaffected fully HLA-matched sibling - Unaffected fully phenotypically HLA-matched related donor - Fully HLA-matched unrelated donor - Unrelated donor with single allele or antigen level mismatch at DQB1 - Unrelated donor with single allele level mismatch at class 1 (HLA-A, -B, or -C) Exclusion Criteria: - Patients with idiopathic aplastic anemia, Fanconi anemia, dyskeratosis congenita, and congenital neutropenia - Patients with MDS as defined by the World Health Organization (WHO) or leukemia - Prior allogeneic HCT - Patient's weight =< 10.0 kg (actual body weight and adjusted body weight) at time of study enrollment - Lansky (patients < 16 years of age) or Karnofsky (patients >= 16 years of age) performance < 70% - Left ventricular ejection fraction < 50% by echocardiogram or multi-gated acquisition (MUGA) scan * For patients unable to obtain a left ventricular ejection fraction, left ventricular shortening fraction of < 26% - Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected/adjusted for hemoglobin) < 50%, forced expiratory volume (FEV)1 < 50% predicted, and forced vital capacity (FVC) < 50% predicted - For patients unable to perform pulmonary function tests (PFTs) due to age or developmental delay: oxygen (O2) saturation < 92% on room air - On supplemental oxygen - Estimated creatinine clearance < 60 mL/minute/1.73m^2 (estimated per institutional practice) - Dialysis dependent - Conjugated bilirubin > 2 x upper limit of normal for age (ULN, unless attributable to Gilbert's syndrome) - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 4 x ULN for age, or - Fulminant liver failure or cirrhosis - Iron overload - This exclusion criterion only applies to patients who are considered at risk for hepatic or cardiac iron overload. Therefore, not all patients enrolled on this protocol will undergo formal hepatic or cardiac iron assessment - For patients >= 18 years with a history of significant transfusions defined as >= 8 packed red blood cell transfusions per year for >= 1 year or have received >= 20 packed red blood cell transfusions (lifetime cumulative) will require formal hepatic and cardiac iron measurement. In addition, patients with a prior history of hepatic or cardiac iron overload will also require formal assessment for iron overload. Patients are excluded if: - Hepatic iron content >= 8 mg Fe/g dry weight by liver magnetic resonance imaging (MRI) using a validated methodology (such as T2 * MRI or ferriscan) or liver biopsy per institutional practice - Cardiac iron content < 25 msec by cardiac T2 * MRI - For patients < 18 years old with a history of significant transfusions defined as >= 8 packed red blood cell transfusions per year for >= 1 year or have received >= 20 packed red blood cell transfusions (lifetime cumulative) will require formal hepatic iron measurement. In addition, patients with a prior history of liver iron overload will also require formal assessment for iron overload. Patients are excluded if: - Hepatic iron content >= 8 mg Fe/g dry weight by liver MRI using a validated methodology (such as T2 * MRI or ferriscan) or liver biopsy per institutional practice - Uncontrolled bacterial infection within 1 week of study enrollment. Uncontrolled is defined as currently taking medication with no clinical improvement or progression on adequate medical treatment - Uncontrolled viral or fungal infection within 30 days of study enrollment. Uncontrolled is defined as currently taking medication with no clinical improvement or progression on adequate medical treatment - Positive for human immunodeficiency virus (HIV) - Presence of clinically significant anti-donor human leukocyte antigen (HLA)-antibodies per institutional practice - Prior solid organ transplant - Patients with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ - Females who are pregnant or breast-feeding - Females and males of childbearing potential who are unwilling to practice an effective method of contraception or agree to abstinence from the time of signing informed consent through 12 months post-transplant or off tacrolimus whichever is later - Known hypersensitivity to treosulfan or fludarabine - Known life-threatening reaction (i.e. anaphylaxis) to Thymoglobulin that would prohibit use for the patient as this study requires use of the Thymoglobulin preparation of anti-thymocyte globulin (ATG) |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Michigan Medical Center | Ann Arbor | Michigan |
| United States | Children's Healthcare of Atlanta | Atlanta | Georgia |
| United States | Children's Hospital Colorado | Aurora | Colorado |
| United States | Johns Hopkins University | Baltimore | Maryland |
| United States | Boston Children's Hospital | Boston | Massachusetts |
| United States | Roswell Park Comprehensive Cancer Center | Buffalo | New York |
| United States | Cincinnati Children's Hospital | Cincinnati | Ohio |
| United States | Nationwide Children's Hospital | Columbus | Ohio |
| United States | Duke University Medical Center | Durham | North Carolina |
| United States | MD Anderson Cancer Center | Houston | Texas |
| United States | Texas Children's Hospital | Houston | Texas |
| United States | Children's Hospital Los Angeles | Los Angeles | California |
| United States | Medical College of Wisconsin/Children's Hospital of Wisconsin | Milwaukee | Wisconsin |
| United States | University of Minnesota | Minneapolis | Minnesota |
| United States | Vanderbilt University Medical Center | Nashville | Tennessee |
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
| United States | Oregon Health & Science University | Portland | Oregon |
| United States | Cohen Children's Hospital of NY | Queens | New York |
| United States | St. Louis Children's Hospital | Saint Louis | Missouri |
| United States | Primary Children's/University of Utah | Salt Lake City | Utah |
| United States | Rady Children's Hospital/UCSD | San Diego | California |
| United States | University of California San Francisco | San Francisco | California |
| United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| Fred Hutchinson Cancer Center | Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Marrow Donor Program |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS) | The primary endpoint is the incidence of 1-year GVHD free, EFS (GEFS). An event is defined as death due to any cause, graft rejection/failure, or 2nd HCT whichever occurs first. Grade III-IV acute GVHD and chronic GVHD (using NIH consensus criteria) requiring systemic immune suppression will be considered in this estimate | 1 year post-HCT | |
| Secondary | Overall Survival | Overall survival at day 100 after HCT | Day 100 post-HCT | |
| Secondary | Overall Survival | Overall survival at 6 months after HCT | 6 months post-HCT | |
| Secondary | Overall Survival | Overall survival at 1 year after HCT | 1 year post-HCT | |
| Secondary | Event-Free Survival | Event-free survival will be estimated at 12 months after HCT. Grade III-IV acute GVHD and chronic GVHD requiring systemic immune suppression will be considered in this estimate. An event is defined as death due to any cause, primary or secondary graft failure/rejection, or 2nd HCT whichever occurs first | 1 year post-HCT | |
| Secondary | Hematologic Recovery: Neutrophil recovery | Hematologic recovery will be assessed according to neutrophil recovery after transplant. Neutrophil recovery is defined as achieving an absolute neutrophil count (ANC) = to 500/mm3 for 3 consecutive measurements on 3 different days. The first of the three days will be designated the day of neutrophil recovery. The competing event is death without neutrophil recovery. | Assessed up to 1 year post-HCT | |
| Secondary | Hematologic Recovery: Platelet recovery | Hematologic recovery will be assessed according to platelet counts recovery after transplant. Platelet recovery is defined as the first day of a minimum of 3 days that the patient has a sustained platelet count = 20,000/mm3 with no platelet transfusions in the preceding 7 days. The first day of sustained platelet count above these thresholds will be designated the day of platelet engraftment. | Day 100 post-HCT | |
| Secondary | Donor Chimerism (CD3 and Myeloid) | Proportions of patients with full (>95%), mixed (5-95%), or rejection (<5%) myeloid | Day 28 post-HCT | |
| Secondary | Donor Chimerism (CD3 and Myeloid) | Proportions of patients with full (>95%), mixed (5-95%), or rejection (<5%) myeloid | Day 100 post-HCT | |
| Secondary | Donor Chimerism (CD3 and Myeloid) | Proportions of patients with full (>95%), mixed (5-95%), or rejection (<5%) myeloid | 1 year post-HCT | |
| Secondary | Primary graft failure/rejection | Defined as never achieving ANC = 500/µL or never achieving = 5% donor myeloid chimerism assessed by peripheral blood chimerism assays by day +42 post-HCT. Second infusion of hematopoietic cells is also considered indicative of primary graft failure by day +42 post-HCT | Day 42 post-HCT | |
| Secondary | Secondary graft failure/rejection post-HCT | Defined as < 5% donor myeloid chimerism in peripheral blood beyond day +42 post-HCT in patients with prior documentation of hematopoietic recovery with = 5% donor cells by day +42 post-HCT. Second infusion of hematopoietic cells is also considered indicative of secondary graft failure. | Assessed up to 1 year post-HCT | |
| Secondary | Grade II-IV and grade III-IV GVHD at day 100 | The cumulative incidences of acute grade II-IV and III-IV GVHD at day 100 after HCT will be determined. | Day 100 post-HCT | |
| Secondary | Grade II-IV and grade III-IV GVHD at day 180 | The cumulative incidences of acute grade II-IV and III-IV GVHD at day 100 after HCT will be determined. | Day 180 post-HCT | |
| Secondary | Chronic GVHD | The cumulative incidence of chronic GVHD (using NIH consensus criteria) requiring systemic immune suppression at 1 year after HCT will be determined. Data will be collected directly from providers and chart review as defined by the NIH Consensus Conference Criteria | 1 year post-HCT | |
| Secondary | Incidence of grade 3-5 toxicities | Grade 3-5 toxicities by day 30 after HCT | Day 30 post-HCT | |
| Secondary | Incidence of grade 3-5 toxicities | Grade 3-5 toxicities by day 100 after HCT | Day 100 post-HCT | |
| Secondary | Incidence of grade 2-3 systemic infections | All microbiologically documented infections or significant infections requiring antibiotic/antifungal therapy occurring up to 6 months after HCT | 6 months post-HCT | |
| Secondary | Incidence of Epstein Barr virus (EBV) reactivation requiring therapy | The incidence of EBV reactivation requiring therapy in the first 180 days after HCT, and of EBV-associated lymphoproliferative disorder in the first 180 days after HCT will be evaluated. | Day 180 post-HCT | |
| Secondary | Incidence of EBV-associated lymphoproliferative disorder | Day 180 post-HCT | ||
| Secondary | Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT | Up to day 180 post-HCT |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04432584 -
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
|
Phase 3 | |
| Completed |
NCT05828485 -
Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects
|
Phase 1 | |
| Recruiting |
NCT02179359 -
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
|
N/A | |
| Active, not recruiting |
NCT04434092 -
A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
|
Phase 3 | |
| Terminated |
NCT05131204 -
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
|
Phase 3 | |
| Recruiting |
NCT01374360 -
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
|
||
| Active, not recruiting |
NCT05389449 -
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
|
Phase 3 | |
| Recruiting |
NCT06100900 -
Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria
|
Phase 1 | |
| Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A | |
| Completed |
NCT06326814 -
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
|
Phase 1 | |
| Completed |
NCT04463056 -
Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH
|
Phase 3 | |
| Recruiting |
NCT05476887 -
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
|
Phase 2 | |
| Completed |
NCT01192399 -
Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06051357 -
Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
|
Phase 2 | |
| Recruiting |
NCT06154512 -
A Real-world, Multi-center, Prospective, Observational Study for PNH in China
|
||
| Completed |
NCT04128943 -
Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
||
| Active, not recruiting |
NCT03329365 -
Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
|
||
| Recruiting |
NCT05755867 -
Global PNH Patient Registry
|
||
| Completed |
NCT04679103 -
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)
|
Phase 3 | |
| Completed |
NCT05642585 -
A Study of Single-dose MY008211A in Healthy Adults
|
Phase 1 |